NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS

Abstract

Bevacizumab (Bev) is currently available for recurrent glioblastoma to improve a patient’s quality of life (QoL). To maintain a patient’s daily life activity, Bev is sometimes continued beyond radiographical progression until neurological deteriorations. However, the benefit of continuous use of Bev in its terminal stage is not clarified. To clarify the benefit, we retrospectively analyzed clinical data of glioblastoma patients in the terminal stage. Ninety-five patients, who died by supra-tentorial newly-diagnosed glioblastoma progression from 2008 to 2018, were included. Bevacizumab use in the last 90 days, living time at home or final place of death were retrospectively analyzed. Of 95, twenty-six received Bevacizumab beyond progression in the last 90 days (Bev-group), and 49 did not (non-Bev group). The median overall survival time is not different between both, and the number of patients, who died at home, is seven (26.9%) and six (12.2%), respectively. Mean final administration day from death is 49.2 days and the mean living time at home in the last 90 days is 49.2 days in the Bev group, which is statistically longer than 24.0 days of the non-Bev group (p=0.0016).To continue Bev beyond progression prolongs the living time at home in the last 90 days in glioblastoma patients, and Bev should be considered in its palliative care.